Načítá se...
Steroid sidestep: Evading androgen ablation by abiraterone
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abir...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4359949/ https://ncbi.nlm.nih.gov/pubmed/25432158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2899 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|